Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irofulven in Relapsed or Refractory Non-Small Cell Lung Cancer
NCT00003666Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 1998
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irofulven in non-small cell lung cancer (NSCLC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Response Rate. Started Nov 1998; status: completed.
02
Drugs
irofulven
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00003666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003666.